<DOC>
	<DOC>NCT02918305</DOC>
	<brief_summary>The REQUIRE STUDY is a multi-center, randomized, double-blind, sham-controlled study, which aims to confirm the efficacy and safety of PRDS-001 (ReCor Medical Inc. ParadiseÂ® in Europe) for renal denervation therapy in patients with treatment resistance hypertension, in comparison with the sham procedure.</brief_summary>
	<brief_title>Renal Denervation on Quality of 24-hr BP Control by Ultrasound In Resistant Hypertension</brief_title>
	<detailed_description>Patients with treatment resistance hypertension is defined patients being treated on 3 or more different classes of antihypertensive medications including diuretics.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>average office systolic BP of 150 mmHg or greater and office diastolic BP of 90 mmHg or greater (both in the sitting position) 24hr ambulatory BP 140 mmHg or greater. Secondary hypertension (sleep apnoea can be included.) Type I diabetes or uncontrolled Type II diabetes with HbA1c 8.4% or greater Known or concurrent chronic active inflammatory bowel diseases (e.g. Crohn's disease, ulcerative colitis etc.) eGFR&lt;40 mL/min/1.73m2 (per predictive equation Japanese Society of Nephrology) Known severe cardiovascular events within 3 months or severe cerebrovascular events Patients those who are planned to receive PCI or other operation for iscaemic cardiovascular disease within 8 months Concurrent persistent atrial fibrillation Patients those who are on active implantable medical devices Primary pulmonary hypertension Patients those who are contraindicated to, or confirmed to have intolerable anaphylactic reaction or uncontrollable allergy to contrast media</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>denervation</keyword>
	<keyword>resistant hypertension</keyword>
</DOC>